Iterum Therapeutics’ $80 Million Initial Public Offering


Cooley advised Iterum Therapeutics plc on its $80 million initial public offering of 6,150,000 ordinary shares.

The underwriters have a 30-day option to purchase up to an additional 922,500 shares.

Leerink Partners and RBC Capital Markets acted as joint book-running managers for the offering. Guggenheim Securities acted as lead manager. Needham & Company acted as co-manager.

Iterum is an Irish clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. The company, led by Corey N Fishman, Judith M Matthews and

Jeff Schaffnit, is based in Chicago. The company’s shares now trade on the Nasdaq Global Market under the symbol “ITRM.”

Cooley advised with a team including Charlie Kim (Picture), Alan Hambelton, Colleen Badgley, Julia Stark, Shivani Agarwal, Brian Woodard, Natasha Leskovsek, Phil Mitchell, Rena Kaminsky, Erin Umberg, Bill Christiansen, Aaron Nudelman, Mark Windfeld-Hansen, Susan Cooper Philpot and John McKenna.

Involved fees earner: Charlie Kim – Cooley LLP; Alan Hambelton – Cooley LLP; Colleen Badgley – Cooley LLP; Julia Stark – Cooley LLP; Shivani Agarwal – Cooley LLP; John McKenna – Cooley LLP; Natasha Leskovsek – Cooley LLP; Phil Mitchell – Cooley LLP; Rena Kaminsky – Cooley LLP; Erin Umberg – Cooley LLP; Bill Christiansen – Cooley LLP; Aaron Nudelman – Cooley LLP; Mark Windfeld-Hansen – Cooley LLP; Susan Cooper Philpot – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Iterum Therapeutics Plc;